PremiumThe FlySonoma Pharmaceuticals announces relaunch of dermatology, eye care lines FDA grants Sonoma 510(k) approval for Microdacyn Hydrogel Sonoma Pharmaceuticals reports Q2 (59c) vs ($5.75) last year PremiumThe FlySonoma Pharmaceuticals trading halted, news pending Sonoma Pharmaceuticals Stockholders Decide on Key Governance Issues Sonoma, MicroSafe announce Australian TGA approval for NanoCyn extended claims PremiumCompany AnnouncementsSonoma Pharmaceuticals Presents Business and Financial Update Sonoma expands Microcyn NPWT Solution products in the U.S. Sonoma Pharmaceuticals reports publication highlighting Microdox potential 
